Label: TESTONE CIK- testosterone cypionate, alcohol

  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated November 1, 2018

If you are a consumer or patient please visit this version.



    Rx Only


    Testosterone cypionate injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.

    Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils.

    The chemical name for testosterone cypionate is androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17β)-. Its molecular formula is C 27H 40O 3, and the molecular weight 412.61.

    The structural formula is represented below:

    Chemical Structure

    Testosterone cypionate injection is available in one strength, 200 mg/mL testosterone cypionate. Each mL of the solution contains Testosterone Cypionate, 200 mg; Benzyl Benzoate, 0.2 mL; Cottonseed Oil, 560 mg; Benzyl Alcohol (as preservative), 9.45 mg.


    Endogenous androgens are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorous, and decreased urinary excretion of calcium. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.

    Androgens are responsible for the growth spurt of adolescence and for eventual termination of linear growth, brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates, but may cause disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. Androgens have been reported to stimulate production of red blood cells by enhancing production of erythropoietic stimulation factor.

    During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).

    There is a lack of substantial evidence that androgens are effective in fractures, surgery, convalescence, and functional uterine bleeding.


    Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus, testosterone cypionate can be given at intervals of two to four weeks.

    Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.

    About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone is metabolized to various 17-keto steroids through two different pathways.

    The half-life of testosterone cypionate when injected intramuscularly is approximately eight days.

    In many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.


    Testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

    1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy.
    2. Hypogonadotropic hypogonadism (congenital or acquired)-idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.

    1. Known hypersensitivity to the drug
    2. Males with carcinoma of the breast
    3. Males with known or suspected carcinoma of the prostate gland
    4. Women who are or who may become pregnant
    5. Patients with serious cardiac, hepatic or renal disease

    Hypercalcemia may occur in immobilized patients. If this occurs, the drug should be discontinued.

    Prolonged use of high doses of androgens (principally the 17-α alkyl-androgens) has been associated with development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis – all potentially life-threatening complications.

    Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.

    There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as testosterone cypionate. Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with testosterone cypionate and initiate appropriate workup and management.

    Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal or hepatic disease.

    Gynecomastia may develop and occasionally persists in patients being treated for hypogonadism.

    This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.

    Androgen therapy should be used cautiously in healthy males with delayed puberty. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.

    This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.



    Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.

    Testosterone cypionate should not be used interchangeably with testosterone propionate because of differences in duration of action.

    Testosterone cypionate is not for intravenous use.

    Information for patients:

    Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, ankle swelling, too frequent or persistent erections of the penis.

    Laboratory tests:

    Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration.

    Serum cholesterol may increase during androgen therapy.

    Drug interactions:

    Androgens may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.

    Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

    In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements.

    Drug/Laboratory test interferences:

    Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T 4 serum levels and increased resin uptake of T 3 and T 4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.


    Animal data.

    Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically-induced carcinomas of the liver in rats.

    Human data.

    There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.

    Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.


    Teratogenic Effects.

    Pregnancy Category X. (See CONTRAINDICATIONS.)

    Nursing mothers:

    Testosterone cypionate is not recommended for use in nursing mothers.

    Pediatric use:

    Safety and effectiveness in pediatric patients below the age of 12 years have not been established.


    The following adverse reactions in the male have occurred with some androgens:

    Endocrine and urogenital: Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high dosages.

    Skin and appendages: Hirsutism, male pattern of baldness, seborrhea, and acne.

    Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.

    Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (see WARNINGS).

    Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.

    Nervous system: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.

    Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions.

    Vascular Disorders - venous thromboembolism

    Miscellaneous: Inflammation and pain at the site of intramuscular injection.

    To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or


    Controlled Substance Class:

    Testosterone is a controlled substance under the Anabolic Steroids Control Act, and Testosterone Cypionate Injection has been assigned to Schedule III.


    There have been no reports of acute overdosage with the androgens.


    Testosterone cypionate injection is for intramuscular use only.

    It should not be given intravenously. Intramuscular injections should be given deep in the gluteal muscle.

    The suggested dosage for testosterone cypionate injection varies depending on the age, sex, and diagnosis of the individual patient. Dosage is adjusted according to the patient's response and the appearance of adverse reactions.

    Various dosage regimens have been used to induce pubertal changes in hypogonadal males; some experts have advocated lower dosages initially, gradually increasing the dose as puberty progresses, with or without a decrease to maintenance levels. Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.

    For replacement in the hypogonadal male, 50 to 400 mg should be administered every two to four weeks.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and shaking the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended.


    Testosterone Cypionate Injection, USP, 200 mg/mL is available as follows:

    1 mL vials                     NDC 0574-0820-01
    10 mL vials                   NDC 0574-0820-10

    Vials should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Use carton to protect contents from light until used.

    Manufactured By
    PharmaForce, Inc.
    Hilliard, OH 43026

    Manufactured For
    Minneapolis, MN 55427

    9Z800 RC J2

    Rev 06-14 B


    Testosterone Cypionate Injection, USP, 200 mg/mL is available as follows:

    1 mL vials                     NDC 0574-0820-01
    10 mL vials                   NDC 0574-0827-10

    Vials should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Use carton to protect contents from light until used.

    Made in Portugal

    Manufactured By

    Hikma Farmacéutica SA

    Terrugem Sintra, Portugal

    Distributed By


    Minneapolis, MN 55427

    8Z100 RC J3

    Rev 06-14 B



    Active Ingredient                                       Purpose

    Isopropyl Alcohol 70% v/v                         Antiseptic

  • Use:

    For preparation of the skin prior to injection.

  • Warnings:

    • For external use only
    • Flammable, keep away from flame or fire
    • Not for use with electrocautinary devices or procedures
    • Do not use in eyes
  • Indications and Usage:

    Stop use and ask a doctor if:

    • Irritation or redness develops
    • condition persists for more than 72 hours
    • Cleansing of an injection site
  • Keep out of reach of children.

    In case of accidental ingestion, seek professional assistance or consult a poison control center immediately.

  • Directions:

    Wipe injection site vigorously and discard

  • Other information:

    • Store at room temperature: 15 deg C to 30 deg C   59 deg F to 86 deg F
    • avoid excessive heat
  • Inactive Ingredient

    Inactive Ingredient

    • Water
  • Principal Display Panel - Carton Label

    NDC 0574- 0820-01

    Testosterone CIII
    Injection, USP

    200 mg/mL

    For Intramuscular
    Use Only

    One 1 mL
    Sterile Vial Perrigo

    Principal Display Panel - Carton Label
  • Principal Display Panel - Case Label

    1 Pad Medium

    NDC# 67777-120-13

    Sterile Alcohol
    Prep Pad

    For External Use Only

    Sterile unless pouch
    is opened or damaged
    Saturated with 70%

    Isopropyl Alcohol

    Latex Free

    Made in China Reorder No. 1113

    Principal Display Panel - Case Label

    NDC: 76420-650-01 RX-Only

    Testone CIK™ CIII

    Kit Contains

    1 Testosterone Cypionate Injection, USP 200mg/mL (1mL)

    1 Isopropyl Alcohol 70% Prep Pad

    1 Pair Nitrile Powder Free Sterile Gloves (M)

    1 Drape

    1 Adhesive Bandage

    5 Non Sterile 4x4 Gauze

    Needles and Syringes Not Included

    1 Dose

    Single Use Only

    Distributed by:



    Torrance, CA 90501

    Principal Display Panel - Kit Label
    testosterone cypionate, alcohol kit
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:76420-650
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:76420-650-01 1 in 1 CARTON; Type 1: Convenience Kit of Co-Package 05/23/2016
    Quantity of Parts
    Part # Package Quantity Total Product Quantity
    Part 1 1 VIAL, GLASS 1 mL
    Part 2 1 POUCH 1.4 mL
    Part 1 of 2
    testosterone cypionate injection, solution
    Product Information
    Route of Administration INTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Inactive Ingredients
    Ingredient Name Strength
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 1 in 1 CARTON
    1 1 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040530 12/21/2007
    Part 2 of 2
    alcohol swab
    Product Information
    Item Code (Source) NDC:67777-120
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Inactive Ingredients
    Ingredient Name Strength
    WATER (UNII: 059QF0KO0R)  
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 1.4 mL in 1 POUCH; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC monograph final part344 03/01/2010
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    unapproved drug other 12/21/2007
    Labeler - Asclemed USA, Inc. (059888437)